

# Validation of High Performance of Liquid Chromatography Method for the Determination of Levonorgestrel and Ethinyl Estradiol in Tablets

Andi Suhendi

Faculty of Pharmacy, Universitas Muhammadiyah Surakarta, Indonesia

Abstract-

The objective of this research was to develop and validate a simple, specific and accurate reverse phase of high performance of liquid chromatographic method for the determination of levonorgestrel (LVG) and ethinylestradiol (EE) in tablets. The chromatographic system included column SunFire ODS (150 mm × 4.6 mm i.d., particle size at 5  $\mu$ m), mobile phase consisting of acetonitrile: methanol: aquabidest (60:15:25) with the flow rate of 1 mL/minute and effluents monitored at 230 nm. The validation of RP HPLC method for the simultaneous determination of LVG and EE was determined by accuracy, precision, linearity, and limit of detection (LOD) as well as the limit of quantitation (LOQ) parameters. The linearity range of both drugs was 1-70  $\mu$ g/mL and 2-14  $\mu$ g/mL for LVG and EE, respectively. The recoveries of LVG and EE were at 101.78% and 102.44% with the coefficients of variation of 0.94% and 1.92%, successively. The LOD of LVG and EE value were of 0.84  $\mu$ g/mL and 0.03  $\mu$ g/mL, and LOQ value were of 2.79 and 0.09 $\mu$ g/mL, respectively.

#### Conclusion:

RP-HPLC method for the simultaneous determination of LVG and EE was simple, rapid and valid.

Keywords: Levonorgestrel, ethinylestradiol, validation.

### INTRODUCTION

Levonorgestrel is a synthetic progestogen [1] used both as an effective, safe and emergency contraception and as an alternative or a combination of hormonal replacement therapy (HRT) [2]. Oral levonorgestrel is perfectly absorbed and does not undergo hepatic metabolism (first pass effect). Serum levels are achieved within  $1.1 \pm 0.4$ hours depending upon the dose and individual variation [3]. Other studies have mentioned that after the administration of levonorgestrel, the levels per oral 64 nmol/L per vaginal and 10.7 nmol/L will be achieved much faster time after oral administration of 1.4 hour to 6.6 hours per vaginal [4].

Research on the determination of levonorgestrel has reported such as radioimmunoassay [5], chemiluminescent immunoassay [6], spectrophotometry [7], voltammetry [8], HPTLC [9]; [10], capillary electrophoresis [11], HPLC [12,13], LC-MS/MS [14-17], GC / MS [18], and GC-MS/MS [19] in human plasma, HPLC-UV in rat plasma [20] and HPLC in pharmaceutical preparations [21]. It also reported the determination of levonorgestrel levels in water samples from the environment or municipal waste stream with GC-MS method, LC-ESI/MS, LC-APCI/MS and LC-MS/MS [22-24], HPLC with a cloud point extraction [25].

Though playing an important role in contraception, levonorgestrel has some serious side effects such as irregular period menstruation, changes in libido, and breast cancer [26]. Pharmacologic and toxic effect depends upon the doses of the regiment. It is necessary to determine the active substances in the product to ensure the quality and safety for consumer.

No research has been found that conducted the assay of levonorgestrel and ethinylestradiol in tablets by chromatographic techniques using a detector PDA (Photo Diode Array) so far. The advantages of the PDA detector are the capabilities in detecting multiple wavelengths simultaneously, analyzing the peak purity, and possibility to be used for kinetic studies [27]. Previous research can be developed to obtain a better separation with several modifications such as the composition and kinds of solvent and flow rates. Therefore, it is necessary to develop and validate a procedure to simultaneously determine levonorgestrel and ethinylestradiol in tablet preparations by reversed-phase HPLC.

#### MATERIALS AND METHODS

# Materials

HPLC Waters Alliance 2965 with PDA 2998 detector, software Empower, stationary phase SunFire C18 (150 x 4.6 mm, particle size 5  $\mu$ m), sonificator (Branson), Millipore filter (Acrodisc 25 mm PVDF 0.45  $\mu$ m), vortex (MaxiMax II), analytical balance (AND with sensitivity 0.01 mg), Levonorgestrel standard (pharmaceutical grade from PT. Triyasa Naga Mas Farma), ethinyl estradiol 95% of purity (Beijing Zizhu Tiangong Science And Technology Co., LTD), tablet contraception (factory A, B, and C), Methanol (E. Merck), acetonitrile (E. Merck), Aquabidest (PT. Ika Pharmindo Putramas)..

#### Instrumentation

HPLC with automatic sampler, Stationary phase SunFire C18 (150 x 4.6 mm, particle size 5  $\mu$ m), mobile phase of acetonitrile: methanol: water (60:15:25), and detection with PDA at  $\lambda = 230$  nm.

## PROCEDURE

# **Preparation procedure**

The uniformity of dosage units of contraception tablets was performed based upon USP [32]. It was started by accurately weighing 10 tablets individually and calculating the content, as expressed by % of label claim. The procedure of uniformity of contraception tablet weight was performed individually until reaching 10 weighed tablets. Then the average concentration of tablet and standard deviation was calculated. The tablets were crushed and sieved in which the powder obtained was weighed approximately at 80.0 mg. The samples were diluted by adding methanol to 5.0 mL and sonificated for 10 minutes. The solution then was filtered by Millipore and injected to HPLC.

#### Validation

Accuracy and precision. To study the reliability and suitability of the developed method, tablet samples were added with three concentration levels of levonorgestrel and ethinylestradiol. Intra-day precision was determined by analysing one concentration level of levonorgestrel and ethinylestradiol in one day, while inter-day precision was determined within three consecutive days. Each sample was determined in 6 replicates. The result was then compared with the standard of requirement [28]

**Linearity.** To study the linearity range of levonorgestrel and ethinylestradiol, seven serial dilutions were prepared by mixing standard stock solutions in the range of 1-70  $\mu$ g/mL for levonorgestrel and 2-14  $\mu$ g/mL for ethinylestradiol, respectively. The peak areas of samples were recorded. The slope and intercept of the calibration graph were obtained by the linear regression of peak area versus concentration: y = bx + a where x refers to the concentration and y refers to the peak area. The linearity was assessed by linear regression analysis, which was calculated by the least square method. The coefficient regression was compared by the standard of requirement [29].

**Sensitivity.** The sensitivity of the method was determined by means of the limit of detection (LOD) and limit of quantitation (LOQ); both of which were calculated based on a statistical method through a linear regression. LOD was calculated based on the standard deviation of the calibration curve (s) and the slope of curve (S), using the equation LOD =  $3 \times SD/b$ . LOQ meanwhile was calculated by the equation LOQ =  $10 \times SD/b$ .

#### **RESULTS AND DISCUSSION**

# Determination of levonorgestrel and ethinylestradiol in tablets

Research on the determination of levonorgestrel and ethinylestradiol in tablet dosage was previously carried out by Prasad et al., [21] using the reversed-phase HPLC method with mobile phase acetonitrile and water (42:58), flow rate of 2.2 mL/min and effluent monitored by UV detector at  $\lambda$  210 nm. The value of separation resolution was 6 and the retention time of ethinylestradiol and levonorgestrel was within 3.34 minutes and 4.89 minutes, respectively. Modification chromatographic system from Prasad et al. [21] was the changes of composition and flow rates of mobile phase and the use of PDA detector. Optimum mobile phase was decided based on the resolution value and number of theoretical plates. The results of the optimization phase were acetonitrile: methanol: aquabidest (60:15:25) with the flow rates at 1.0 mL/minute. In addition to perform the optimization of mobile phase, the optimization of wave length was also performed to obtain an appropriate wave length (Figure 1).




Figure 1. Chromatographic of separation of levonorgestrel and ethinylestradiol

In the reversed-phase HPLC system ethinylestradiol and levonorgestrel mixture would be separated in order. Water of levonorgestrel and ethinylestradiol contained the solubility of 2.05 mg/mL and 11.30 mg/mL, respectively [30]. In this case ethinylestradiol appeared faster due to its weaker relative solubility to the mobile phase and inter molecular forces with stationary phase. Levonorgestrel here emerged in the second time in view of the stronger intermolecular forces on the non-polar stationary phase. The type of inter-molecular interactions between levonorgestrel and stationary phase (ODS) is called Van der Waals forces. Retention time for ethinylestradiol and levonorgestrel were achieved in 2.320 and 2.991 minutes, respectively.

#### Validation Parameters

#### Accuracy

The determination of accuracy is very important parameters in the method of quantitative analysis as this parameter shows if systematic or random errors occur. There are several techniques to determine accuracy such as spike method, addition method, and comparison method with standard method. In this research, accuracy parameters were obtained by addition method.

The accuracy (Table 1) showed that good recoveries and RSD that agree with acceptance criteria. Acceptance criteria for accuracy with a concentration level of 10-100  $\mu$ g/mL were 90-107% and RSD value of 5.3% [28].

Table 1. *Recovery* of Levonorgestrel and Ethinylestradiol (n=3)

| Concentration<br>added (%) | Recovery<br>EE (%) | Recovery<br>LVG<br>(%) | RSD of<br><i>Recovery</i><br>EE (%) | RSD of<br><i>Recovery</i><br>LVG<br>(%) |
|----------------------------|--------------------|------------------------|-------------------------------------|---|
| 80                         | 104.33             | 105.00                 | 0.90                                | 1.29                                    |
| 100                        | 99.33              | 98.33                  | 2.11                                | 0.88                                    |
| 120                        | 103.67             | 101.67                 | 2.76                                | 0.65                                    |
| Average (%)                | 102.44             | 101.78                 | 1.92                                | 0.94                                    |

Precision

Precision was described by intra and inter-day precision. The results of determination of intra-day precision (Table 2) showed the RSD value of ethinylestradiol and levonorgestrel were 6.42% and 5.64% respectively. Meanwhile, inter-day precision (Table 2) showed the RSD value of ethinylestradiol and levonorgestrel on different days were at 4.65% and 2.28% respectively. The RSD values of ethinylestradiol and levonorgestrel were in line with the acceptance criteria [28,31].

Table 2. Intra-day and Inter-day Precision

| Precision | %RSD (n=6) |      |  |
|-----------|------------|------|--|
| riccision | LVG        | EE   |  |
| Intra-day | 5.64       | 6.42 |  |
| Inter-day | 2.28       | 4.65 |  |

Linearity Range

Linearity is a parameter that provides a linier response of the method to the changes of sample concentrations. The results of the determination of this parameter are r or  $r^2$  (r square). Acceptance criteria for linearity parameter are the value of the correlation coefficient > 0.98 for sample and > 0.99 for standard measurements [29]. The correlation coefficients ( $r^2$ ) of ethinylestradiol and levonorgestrel were at 0.992 and 0.997, respectively. Linearity range of ethinylestradiol and levonorgestrel were at 2-14 µg/mL and 1-70 µg/mL. These

results were same with the ones obtained by Prasad et al. [21]. This research did not determine the concentration still providing a linear response.

#### Calculation of LOD and LOQ

The determination of the parameters in this study used the calculation method based on the standard deviation of the response (peak area) and the slope of the calibration curve. The results of the limit of detection and limit of quantitation of ethinylestradiol and levonorgestrel were at 0.838 µg/mL; 2.792 µg/mL, and 0.028 µg/mL; 0.092 µg/mL, respectively. LOD and LOQ were obtained by calculation tested by comparing the values with the smallest analytes. A correct method for recording a determination result depending on the quantity of analytical signals is presented in Table 3 [32].

Another technique to determine whether the LOD is acceptable is a 10 x LOD> Cmin and LOD <Cmin. If the results meet these criteria, the LOD value is acceptable then [32]. The calculation results showed that the value of  $C_{min}$  was greater than that of the LOD and less than 10 times compared to the LOD and LOQ values that were acceptable.

| Result, x           | <b>Recording of result</b> |  |  |
|---------------------|----------------------------|--|--|
| X < LOD             | Not determined             |  |  |
| $LOD \le x \le LOQ$ | Not quantified             |  |  |
| $X \ge LOQ$         | Value of concentration     |  |  |

#### Uniformity of Content Evaluation

Content uniformity is required by the USP 32 [33] for a product with the ratio of active substance to the additional material is <25% active substance or content of <25 mg. The acceptance criteria of content uniformity are the result of measurement of 10 tablets that should not be more than L1% (the maximum value allowed). If it is larger than L1%, the measurements will be repeated for the other 20 tablets. Claims on the label for ethinylestradiol and levonorgestrel products A, B and C respectively are at 0.03 mg and 0.15 mg. RSD values of measurements of 10 tablets from three different products were 3.73 and 5.29%; 5.50 and 4.10%; 2.72 and 2.16% for ethinylestradiol and levonorgestrel, product A, B, and C, respectively.

The acceptance of content uniformity values for L1% was at 15.0% of the average value of content compared with the SD value measurements. Calculation results (Table 4) found that all products have met the requirements of the content uniformity.

Table 4. Calculated Content Uniformity of Contraceptive Tablet

| product | Average of concentration<br>in tablet |          | SD    |       | L1%    |        |
|---------|---------------------------------------|----------|-------|-------|--------|--------|
|         | EE (mg)                               | LVG (mg) | EE    | LVĠ   | EE     | LVG    |
| Α       | 0.030                                 | 0.149    | 0.002 | 0.009 | 0.0045 | 0.0224 |
| В       | 0.029                                 | 0.143    | 0.002 | 0.006 | 0.0043 | 0.0214 |
| С       | 0.029                                 | 0.143    | 0.001 | 0.003 | 0.0044 | 0.0214 |

#### CONCLUSION

- The development and validation of reverse-phase 1 HPLC method for the determination of levonorgestrel and ethinylestradiol have been valid. The results of parameters accuracy for levonorgestrel and ethinylestradiol were at 101.78% and 102.44% with RSD, respectively 0.94% and 1.92%. Intra-day and precision of levonorgestrel inter-day and ethinylestradiol were at 5.64% and 6.42%, 2.28% and 4.65%, respectively. Linearity parameters was in the range 1-70 µg/ mL levonorgestrel and ethinylestradiol was in the range 2-14  $\mu$ g/ mL, the value of r<sup>2</sup> = 0.997 and  $r^2 = 0.992$ , respectively. LOD value of levonorgestrel and ethinylestradiol is 0.028 µg/ mL and 0.838  $\mu g/$  mL. LOQ value of levonorgestrel and ethinylestradiol is 0.092  $\mu$ g/ mL and 2.792  $\mu$ g/ mL.
- 2. Modification of chromatographic system had a better separation.

#### REFERENCES

- Food and Drug Administration (FDA). Highlights of Prescribing Information.http://www.accessdata.fda.gov/drugsatfda\_docs/label/20 09/021998lbl.pdf accessed in July, 27, 2010
- 2. UNFPA. Reproductive Health: Guiding Principles for Their Inclusion on National Medicines Lists. Seattle: PATH; 2006, p 82
- AndersonP, Knoben J. Troutman W. Handbook of Clinical Drug Data, 10th Edition, MCGRAW-HILL, New York, 2006. p 666
- Devoto L. Fuentes A. Palomino A. Espinoza A. Kohen P. Ranta S. Hertzen HV. FertilSteril 2005; 84(1): 46-51
- Qi Gui L. Nieuweboer B. Radio immunological Determination of Levonorgestrel and Ethinylestradiol. J. Tongji Med. Univ. 1989; 9(2): 65-73
- Novikova N. Weisberg E. Stanczyk FZ. Croxatto HB. Fraser IS. Effectiveness of Levonorgestrel Emergency Contraception Given Before or After Ovulation-Pilot Study. Contraception. 2007; 75: 112-8.
- Berzas JJ. Rodríguez J. Castañeda G. Simultaneous Determination of Ethinylestradiol and Levonorgestrel in Oral Contraceptives by Derivative Spectrophotometry. Analyst. 1997;122: 41 - 44
- Ghoneim MM. Baumann W. Hammam E. Tawfik A. Voltametric Behaviour and Assay of The Contraceptive Drug Levonorgestrel in Bulk, Tablets, and Human Serum at Mercury Electrode Talanta. 2004; 64(4): 857-64
- Khakpour M. Jamshidi A. Entezami AA. Mirzadeh H. HPTLC Procedure for Determination of Levonorgestrel in Drug-Release Media of an In-situ-Forming Delivery System J Planar Chromatogr. 2005; 18: 326-8
- Amin M. Hassenbach M. Direct Quantitative Thin Layer Chromatographic Determination of Levonorgestrel and Ethinylestradiol in Oral Contraceptives by Diffuse Reflection and Fluorescence Methods Analyst. 1979; 104: 407-11
- 11. Du B. Song S. Shi X. Zhang Z. Analysis of steroids by non-aqueous capillary electrophoresis J Anal Chem. 2009; 64(1):59-64
- Jain S. Sapre R. Tiwary AK. Jain NK. Proultraflexible Lipid Vesicles for Effective Transdermal Delivery of Levonorgestrel: Development, Characterization, and Performance Evaluation. AAPS PharmSciTech. 2005; 6(3): E513-22

- Huang Y. Lin H. Song R. Tian Y. Zhang Z. Optimization of Dispersive Liquid-Liquid Micro extraction for Analysis of Levonorgestrel in Water Samples Using Uniform Design Anal. Methods. 2011;3: 857-64
- Liu F. Xu Y. Liu A. Hu W. Guo Q. LC-Tandem-MS Validation for Quantitative Analysis of Levonorgestrel in Human Plasma .Chromatographia. 2008; 68: 707-12
- Bhargavi P. Lakshmi KS. Ravi KK. Quantitative Bionalysis of Levonorgestrel in Human Plasma using LC-MS-MS.Int J Ins Pharmacy Life Sci; 2011: 1(2): 39-48
- Wang Q. Wu Z. Wang Y. Luo G. Wu E. Gao X. Li G. Determination of Levonorgestrel in Human Serum by Liquid Chromatographic-Electrospray Tandem Mass Spectrometry Anal Lett. 2001; 34: 103-12
- Sun Y. Sun J. Liu J. Yin S. Chen Y. Zhang P. Pu X. Sun Y. He Z. Selective and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Levonorgestrel in Human Plasma. J Chromatogr B. 2000; 813(1-2): 243-53
- Gainer E. Massai R. Lillo S. Reyes V., Forcelledo ML. Caviedes R. Villarroel C. Bouyer J. Levonorgestrel Pharmacokinetics in Plasma and Milk of Lactating Women Who Take 1,5 mg for Emergency Contraception. Hum Reprod. 2007; 22(6): 1578-84
- Kook K. Gabelnick H. Duncan G. Pharmacokinetics of levonorgestrel 0.75 mg tablets .Contraception. 2002: 66: 73–6
- Tang T. Li P. Luo L. Shi D. Li J. Chao Y. Development and validation of a HPLC Method for Determination of Levonorgestrel and Quinestrol in Rat Plasma. Biomed Chromagr. 2010; 24: 706-10
- Prasad SD. Reddy GC. Prasad PSS. Mukkanti. Simultaneous KCKT Estimation of Levonorgestrel and Ethinylestradiol from tablets Indian J Pharm Sci.2001; 66: 231-4
- Labadie P. Budzinski H. Development of an Analytical Procedure for Determination of Selected Oestrogens and Progestogen in Water Samples .Anal Bioanal Chem.2005; 381: 1199-1205
- Diaz-Cruz MS. de Alda MJL. Lopez R. Bacelo D. Determination of oestrogens and progestogens by mass spectrometric techniques (GC/MS, LC/MS and LC/MS/MS). JMass Spectrom.2003; 38: 917– 23
- Vulliet E. Baugros JB. Waton MMF. Loustalot MFG. Analytical Methods for Determination of Selected Steroid sex Hormone and Corticosteroids in Wastewater. AnalBioanal Chem. 2007; 387: 2143-51
- Wang L. Cai YQ. He B. Yuan CG. Shen DZ. Shao J. Jiang GB. Determination of Oestrogens in Water by HPLC-UV Using Cloud Point Extraction.Talanta.2006; 70: 47-51
- Stuart MC. Kouimtzi M. Hill SR. WHO Model Formulary. 2008: 367-368. Switzerland
- Aboul Enein HY. Serignese V. Photodiode-Arrays Detection, in Encyclopaedia of Chromatography. 2002; 1-4. Marcel Deker. New York
- Huber L. Validation and Qualification in Analytical Laboratories. Second Edition. 2007: 125-153. Informal Healthcare, USA,
- Ermer J. Miller JH. Method Validation in Pharmaceutical Analysis, A Guide to Best Practice. 2005: 4-14. WILEY-VCH Verlag GmbH & Co.
- drugbank. Levonorgestrel and ethinylestradiol. www.drugbank.ca/drugs/DB00977,.
- Konieczka P. Namiesnik J. Quality Assurance and Quality Control in the Analytical Chemical Laboratory. 2009: 148-150. CRC Press
- 32. USP 32. Pharmacopoeia Online. www.uspbpep.com,